Eloxx Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q1 2012 to Q3 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Eloxx Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q1 2012 to Q3 2023.
  • Eloxx Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2023 was -321 %, a 184% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2023 -321 -702 -184% Sep 30, 2023
Q2 2023 -623 -780 -496% Jun 30, 2023
Q1 2023 4.8K +4.71K +5230% Mar 31, 2023
Q4 2022 -5.91K -5.99K -7157% Dec 31, 2022
Q3 2022 381 +293 +333% Sep 30, 2022
Q2 2022 157 +52.7 +50.5% Jun 30, 2022
Q1 2022 90.1 -57.5 -39% Mar 31, 2022
Q4 2021 83.8 -20 -19.3% Dec 31, 2021
Q3 2021 88 +5.19 +6.27% Sep 30, 2021
Q2 2021 104 Jun 30, 2021
Q1 2021 148 Mar 31, 2021
Q4 2020 104 Dec 31, 2020
Q3 2020 82.8 Sep 30, 2020
Q3 2017 196 +58.6 +42.7% Sep 30, 2017
Q2 2017 190 +89.2 +88.9% Jun 30, 2017
Q1 2017 125 +41.3 +49.1% Mar 31, 2017
Q4 2016 110 +36.8 +50.1% Dec 31, 2016
Q3 2016 137 +68.8 +100% Sep 30, 2016
Q2 2016 100 +48.2 +92.5% Jun 30, 2016
Q1 2016 84.1 +46.8 +125% Mar 31, 2016
Q4 2015 73.5 +42.6 +138% Dec 31, 2015
Q3 2015 68.7 +44.8 +188% Sep 30, 2015
Q2 2015 52.1 +22.3 +74.6% Jun 30, 2015
Q1 2015 37.4 -11.9 -24.2% Mar 31, 2015
Q4 2014 30.9 -51.6 -62.5% Dec 31, 2014
Q3 2014 23.9 -110 -82.2% Sep 30, 2014
Q2 2014 29.9 -97.5 -76.6% Jun 30, 2014
Q1 2014 49.3 -83.7 -62.9% Mar 31, 2014
Q4 2013 82.5 -40.3 -32.8% Dec 31, 2013
Q3 2013 134 +21.6 +19.3% Sep 30, 2013
Q2 2013 127 +20.1 +18.7% Jun 30, 2013
Q1 2013 133 +29.3 +28.2% Mar 31, 2013
Q4 2012 123 Dec 31, 2012
Q3 2012 112 Sep 30, 2012
Q2 2012 107 Jun 30, 2012
Q1 2012 104 Mar 31, 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.